Show simple item record

dc.contributor.author Alonso, Leonardo Gabriel
dc.contributor.author Cerutti, Maria Laura
dc.contributor.author Risso, Marikena Guadalupe
dc.contributor.author González, Mariángeles
dc.contributor.author Camporeale, Gabriela
dc.contributor.author de Prat Gay, Gonzalo
dc.date.available 2017-02-09T18:26:10Z
dc.date.issued 2011
dc.identifier.citation Alonso, Leonardo Gabriel; Cerutti, Maria Laura; Risso, Marikena Guadalupe; González, Mariángeles; Camporeale, Gabriela; et al.; Desarrollo de una vacuna profilactica de segunda generacion contra el papilomavirus humano; Medicina (buenos Aires); Medicina (buenos Aires); 71; 3; -1-2011; 261-266
dc.identifier.issn 0025-7680
dc.identifier.uri http://hdl.handle.net/11336/12799
dc.description.abstract Human papillomaviruses (HPV) are the etiologic agent for cervical cancer (CC), the second cause of cancer death in women worldwide. It is estimated that half a million new cases are diagnosed each year, mostly in developing countries due to the lack of massive programs for early detection of the virus. Recently, two prophylactic vaccines against the main oncogenic HPV types 16 and 18 (responsible for 80% of CC) have been introduced into market. Both of these vaccines, obtained as recombinants, have been shown to be safe and effective; however, their high cost works against its immediate impact in the incidence of HPV infection in developing and low-income countries. There is a need to have in hand second generation, low cost vaccines of massive use that will decrease CC cases in a large extent. With this in mind, we have developed a recombinant expression platform that allows us to obtain virus-like particles (VLPs) to formulate both effective and accessible vaccines against HPV infection.
dc.description.abstract Human papillomaviruses (HPV) are the etiologic agent for cervical cancer (CC), the second cause of cancer death in women worldwide. It is estimated that half a million new cases are diagnosed each year, mostly in developing countries due to the lack of massive programs for early detection of the virus. Recently, two prophylactic vaccines against the main oncogenic HPV types 16 and 18 (responsible for 80% of CC) have been introduced into market. Both of these vaccines, obtained as recombinants, have been shown to be safe and effective; however, their high cost works against its immediate impact in the incidence of HPV infection in developing and low-income countries. There is a need to have in hand second generation, low cost vaccines of massive use that will decrease CC cases in a large extent. With this in mind, we have developed a recombinant expression platform that allows us to obtain virus-like particles (VLPs) to formulate both effective and accessible vaccines against HPV infection.
dc.format application/pdf
dc.language.iso spa
dc.publisher Medicina (buenos Aires)
dc.rights info:eu-repo/semantics/openAccess
dc.rights.uri https://creativecommons.org/licenses/by-nc-sa/2.5/ar/
dc.subject Papillomavirus
dc.subject Cervical cancer
dc.subject Prophylactic vaccine
dc.subject.classification Biotecnología relacionada con la Salud
dc.subject.classification Biotecnología de la Salud
dc.subject.classification CIENCIAS MÉDICAS Y DE LA SALUD
dc.title Desarrollo de una vacuna profilactica de segunda generacion contra el papilomavirus humano
dc.title Development of a second generation prophylactic vaccine against human papillomavirus
dc.type info:eu-repo/semantics/article
dc.type info:ar-repo/semantics/artículo
dc.type info:eu-repo/semantics/publishedVersion
dc.date.updated 2017-02-07T13:52:37Z
dc.journal.volume 71
dc.journal.number 3
dc.journal.pagination 261-266
dc.journal.pais Argentina
dc.journal.ciudad Buenos Aires
dc.description.fil Fil: Alonso, Leonardo Gabriel. Fundación Instituto Leloir; Argentina. Consejo Nacional de Investigaciones Científicas y Técnicas. Oficina de Coordinación Administrativa Parque Centenario. Instituto de Investigaciones Bioquimicas de Buenos Aires; Argentina. Xbio S.a; Argentina
dc.description.fil Fil: Cerutti, Maria Laura. Consejo Nacional de Investigaciones Científicas y Técnicas. Oficina de Coordinación Administrativa Parque Centenario. Instituto de Investigaciones Bioquimicas de Buenos Aires; Argentina. Fundación Instituto Leloir; Argentina. Xbio S.a; Argentina
dc.description.fil Fil: Risso, Marikena Guadalupe. Fundación Instituto Leloir; Argentina. Consejo Nacional de Investigaciones Científicas y Técnicas. Oficina de Coordinación Administrativa Parque Centenario. Instituto de Investigaciones Bioquimicas de Buenos Aires; Argentina. Xbio S.a; Argentina
dc.description.fil Fil: González, Mariángeles. Consejo Nacional de Investigaciones Científicas y Técnicas. Oficina de Coordinación Administrativa Parque Centenario. Instituto de Investigaciones Bioquimicas de Buenos Aires; Argentina. Fundación Instituto Leloir; Argentina. Xbio S.a; Argentina
dc.description.fil Fil: Camporeale, Gabriela. Consejo Nacional de Investigaciones Científicas y Técnicas. Oficina de Coordinación Administrativa Parque Centenario. Instituto de Investigaciones Bioquimicas de Buenos Aires; Argentina. Fundación Instituto Leloir; Argentina
dc.description.fil Fil: de Prat Gay, Gonzalo. Consejo Nacional de Investigaciones Científicas y Técnicas. Oficina de Coordinación Administrativa Parque Centenario. Instituto de Investigaciones Bioquimicas de Buenos Aires; Argentina. Fundación Instituto Leloir; Argentina
dc.journal.title Medicina (buenos Aires)
dc.relation.alternativeid info:eu-repo/semantics/altIdentifier/url/http://ref.scielo.org/sp5xnb


Archivos asociados

This item appears in the following Collection(s)

Show simple item record

info:eu-repo/semantics/openAccess Excepto donde se diga explícitamente, este item se publica bajo la siguiente descripción: Creative Commons Attribution-NonCommercial-ShareAlike 2.5 Unported (CC BY-NC-SA 2.5)